Selecta has licensed a portfolio of 17 groundbreaking foundational inventions on an exclusive and worldwide basis from MIT, Brigham and Women's Hospital, and Harvard Medical School.  

Building on these breakthroughs, the company's intellectual property estate has grown to more than 80 patent families, including issued patents and pending patent applications in both the United States and international jurisdictions. In addition to Selecta's comprehensive patent estate, the company also has significant proprietary know-how related to the processes that best enable self-assembling of targeted vaccines and large scale manufacturing.